3D Bioprinting Industry worth $2.4 billion by 2029, with a CAGR of 12.7%
The report "3D Bioprinting Market by Component (3D bioprinters (Microextrusion, Inkjet, Laser), Bioinks, Software, Consumable), Material (Hydrogels, ECM), Application(Research (Regenerative Medicine, 3D cell Culture), Clinical (Skin, Bone)) - Global Forecast to 2029", is projected to reach USD 2.4 billion by 2029 from USD 1.3 billion in 2024, at a CAGR of 12.7% during the forecast period The growth in the 3D bioprinting market is fueled by growing adoption of 3D bioprinting technology within the pharmaceutical and cosmetic industries, advancement in the 3D bioprinting technology, rising public and private partnerships and collaborations, increasing investments in R&D and the expenditure on medical devices.
Browse 530 market data Tables and 46 Figures spread through 453 Pages and in-depth TOC on "3D Bioprinting Market by Component (3D bioprinters (Microextrusion, Inkjet, Laser), Bioinks, Software, Consumable), Material (Hydrogels, ECM), Application(Research (Regenerative Medicine, 3D cell Culture), Clinical (Skin, Bone)) - Global Forecast to 2029"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/3d-bioprinting-market-170201787.html
The 3D Bioprinters segment segment is expected to have the dominant share of the 3D bioprinting market in 2023.
Based on component, the global 3D bioprinting market is segmented into 3D bioprinters, bioinks, software and consumables. 3D bioprinters accounted for the larger market share in 2023. The segment is witnessing growth driven by technological innovations and escalating demand for organ transplantation services.
The Research applications segment is expected to account for the largest share of the application segment in the 3D bioprinting market in 2023.
Based on application, the 3D bioprinting market is segmented into research applications and clinical applications. research applications segment accounted for the larger share of the 3D bioprinting market in 2023. The market for research applications is further segmented into drug research, regenerative medicine, and 3D cell culture. Among these, the drug research segment accounted for the largest share of the market during forecast period of 2024-2029, due to the pharmaceutical & biotechnology firms intensifying their integration of 3D bioprinting technology.
The Asia Pacific region is anticipated to grow at significant CAGR during the forecast period.
The Asia Pacific is accounted to be the fastest-growing segment of the market. Large population base and robust domestic manufacturing capabilities for systems, fostering heightened partnerships and collaborations geared towards healthcare enhancement characterized by substantial investment in research and development (R&D), rising demand for organ transplants, rising government funding for advancement of 3D bioprinting technology in the region. Additionally, notable surge in stem cell research activities across several APAC countries, further contributing to the biomedical landscape is driving 3D bioprinting uptake in the region.
The 3D bioprinting market is fragmented, with a large number of players competing for market share.
BICO Group AB (US), 3D Systems, Inc. (US), Merck KGaA (Germany), Organovo Holings Inc (US), CollPlant Biotechnologies Ltd. (Israel), regenHU (Switzerland), Aspect Biosystem Ltd. (Canada), Advanced Solutions Life Sciences, LLC (US), Cyfuse Biomedical K.K (Japan), Rokit Healthcare Inc. (South Korea), Hangzhou Genofei Biotechnology Co., Ltd. (China), Foldink (Armenia), Brinter (US) and 3D bioprinting solution (Russia) and REGEMAT 3D, SL (Spain) are some of the leading players in this market. Most companies in the market focus on organic and inorganic growth strategies, such as product launches, expansions, acquisitions, partnerships, agreements, and collaborations, to increase their product offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.
Comments
Post a Comment